Context Therapeutics (CNTX) Non Operating Income (2021 - 2025)
Context Therapeutics (CNTX) posted Non Operating Income of -$6635.0 for Q1 2025, down 208.32% sequentially from -$2152.0 in Q3 2024, and down 297.88% YoY from $3353.0 in Q1 2024.
Context Therapeutics (CNTX) Non Operating Income (2021 - 2025) Analysis & Trends
Context Therapeutics has reported Non Operating Income for 5 years, with the latest figure at -$6635.0 in Q1 2025.
- Quarterly Non Operating Income fell 297.88% year-over-year to -$6635.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was -$11541.0 (up 78.98% YoY) and the FY2023 annual result came in at -$55570.0, down 2672.95% from the prior year.
- Non Operating Income retreated to -$6635.0 in Q1 2025 per CNTX's latest filing, from -$2152.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $126531.0 in Q3 2021 and troughed at -$61400.0 in Q4 2023.
- A 5-year average of $3422.3 and a median of -$757.5 in 2021 frame the typical range for Non Operating Income.
- The widest YoY moves for Non Operating Income: up 903.2% in 2023, down 305775.0% in 2023.
- Over 5 years, Non Operating Income stood at -$276.0 in 2021, then slumped by 733.7% to -$2301.0 in 2022, then plunged by 2568.41% to -$61400.0 in 2023, then surged by 96.5% to -$2152.0 in 2024, then plunged by 208.32% to -$6635.0 in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered -$6635.0, -$2152.0, and -$6107.0 for Q1 2025, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -6,635.00 |
| Sep 30, 2024 | -2,152.00 |
| Jun 30, 2024 | -6,107.00 |
| Mar 31, 2024 | 3,353.00 |
| Dec 31, 2023 | -61,400.00 |
| Sep 30, 2023 | 15,369.00 |
| Jun 30, 2023 | -12,227.00 |
| Mar 31, 2023 | 2,688.00 |
| Dec 31, 2022 | -2,301.00 |
| Sep 30, 2022 | 1,532.00 |
| Jun 30, 2022 | 4.00 |
| Mar 31, 2022 | -1,239.00 |
| Dec 31, 2021 | -276.00 |
| Sep 30, 2021 | 126,531.00 |
| Jun 30, 2021 | -4,320.00 |
| Mar 31, 2021 | 1,937.00 |